Sjogren's Syndrome Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Sjogren's Syndrome Therapeutics | DelveInsight

DelveInsight's Sjogren's Syndrome Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sjogren's Syndrome therapies in various stages of clinical development. The report provides insights into 20+ companies and 22+ pipeline drugs in the Sjogren's Syndrome pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Sjogren's Syndrome Clinical Trial Landscape Report

• DelveInsight's Sjogren's Syndrome pipeline report depicts a robust space with 20+ companies working to develop 22+ pipeline therapies for Sjogren's Syndrome treatment.
• Key Sjogren's Syndrome companies such as Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, and Amgen.
• Promising Sjogren's Syndrome pipeline therapies in various stages of development include VAY736, VIB4920, BMS-986325, R-2487, RSLV-132, Cenegermin, AMG 329, and others.

Request a sample and discover the recent advances in Sjogren's Syndrome treatment drugs https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Sjogren's Syndrome?

Sjogren's Syndrome (SS) is a chronic autoimmune disease characterized by inflammation of the exocrine glands, predominantly the salivary and lacrimal glands. The immune system inappropriately attacks cells in these glands, resulting in inflammation and damage.
The main consequence of this inflammation is the development of sicca symptoms, including dryness of the mouth and eyes. Other exocrine glands may also be affected, resulting in dryness of the skin, upper respiratory tract, oropharynx, and vagina.
Sjogren's Syndrome is mainly classified into primary and secondary forms. Primary Sjogren's Syndrome occurs without another underlying rheumatic disorder, whereas secondary Sjogren's Syndrome is associated with another systemic autoimmune disease, such as systemic lupus erythematosus, rheumatoid arthritis, or scleroderma.
The characteristic lesion is focal lymphocytic sialadenitis, in which lymphocyte-rich inflammatory cells infiltrate exocrine glandular tissue. In more severe disease, systemic manifestations may involve the lungs, kidneys, skin, joints, and other organs. Rarely, malignant transformation of B lymphocytes can result in non-Hodgkin lymphoma.
Management focuses on replacing moisture at affected glandular sites and reducing the autoimmune response locally and systemically. Autologous serum eye drops and other approaches are also being explored for treatment-resistant dry-eye manifestations.

Emerging Sjogren's Syndrome Drug Profiles

VAY736: Novartis
VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) receptor. The BAFF receptor is predominantly expressed on B cells and plays an important role in B-cell maturation, activation, and survival.
VAY736 competitively inhibits BAFF binding to the BAFF receptor, thereby blocking BAFF-R-mediated signaling in B cells. The molecule is also engineered to effectively eliminate B cells from circulation through antibody-dependent cellular cytotoxicity (ADCC). The molecule is being developed by Novartis in partnership with MorphoSys. Currently, the drug is in Phase III clinical studies for the treatment of Sjogren's Syndrome.

AMG 329: Amgen
AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. The drug is currently in Phase II clinical studies for the treatment of Sjogren's Syndrome.

R-2487: Rise Therapeutics
R-2487 is a targeted oral immune therapy designed to induce T regulatory cell populations. It has a unique mechanism of action through which it can engage specific immune pathways that regulate tolerance and reset T regulatory deficiencies to reduce inflammatory cytokines that contribute to autoimmune disease.

This mechanism is particularly relevant to autoimmune diseases such as Sjogren's Syndrome. Currently, the drug is in Phase I clinical studies for the treatment of Sjogren's Syndrome.

Learn more about the novel and emerging Sjogren's Syndrome pipeline therapies https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Sjogren's Syndrome Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Sjogren's Syndrome Companies: Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen
• Key Sjogren's Syndrome Pipeline Therapies: VAY736, VIB4920, BMS-986325, R-2487, RSLV-132, Cenegermin, AMG 329.

Dive deep into rich insights for new drugs for Sjogren's Syndrome treatment, visit https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Sjogren's Syndrome Pipeline Report Introduction
2. Sjogren's Syndrome Pipeline Report Executive Summary
3. Sjogren's Syndrome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Sjogren's Syndrome Pipeline Therapeutics
6. Sjogren's Syndrome Pipeline: Late Stage Products (Phase III)
7. Sjogren's Syndrome Pipeline: Mid Stage Products (Phase II)
8. Sjogren's Syndrome Pipeline: Early Stage Products (Phase I)
9. Sjogren's Syndrome Pipeline: Preclinical and Discovery Stage Products
10. Sjogren's Syndrome Pipeline Therapeutics Assessment
11. Inactive Products in the Sjogren's Syndrome Pipeline
12. Key Companies
13. Key Products in the Sjogren's Syndrome Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Sjogren's Syndrome pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.